Urotoday International Journal

Home > Email Alerts
Email Alerts
Benefits of Email Alerts:

 

UroToday International Journal's E-Mail Table of Contents helps the professional urology community around the world stay connected to what's new and important in medical research and clinical practice.


Be the first to know what is published in the Journal each week.


Register Here or LOGIN to amend your settings for communications from UroToday and UroToday International Journal.


This is a completely FREE service. There is no cost to receive the UIJ E-Mail Table of Contents.


case diagnosis

Participate Now
CME - Frequently Asked Questions in Improving Detection and Initial Treatment of Bladder Cancer


Presented by the Warren Alpert Medical School of Brown University, Office of Continuing Medical Education.

Target Audience

This activity is designed for urologists and other healthcare professionals interested in or involved with the management of bladder cancer.

Educational Objectives

Upon completion of this activity, participants should be able to:

  1. Discuss the epidemiology of bladder cancer including prevalence, mortality, and risk factors
  2. Describe the economic impact of bladder cancer and how improved techniques for initial detection and at the time of transurethral resection of bladder tumor (TURBT) may decrease the economic burden
  3. Compare and contrast new urine biomarkers when compared to urine cytology
  4. Discuss the role of photodynamic diagnosis using hexaminolevulinate-guided fluorescence cystoscopy in detecting carcinoma in situ and residual disease at the time of TURBT compared to traditional white-light cystoscopy (WLC)
  5. Optimize use of intravesical therapy after TURBT to prevent recurrence of bladder...
    Take CME
CME - Frequently Asked Questions in the Management of Castrate-Resistant Prostate Cancer (CRPC)

An Expert Panel Interview

Educational Objectives

At the conclusion of this activity, participants should be able to:

  • Identify patients with castrate-resistant prostate cancer (CRPC)

  • Review current and future modalities available for the treatment of CRPC.

  • Discuss therapeutic strategies that may mitigate skeletal adverse events associated with metastatic prostate cancer and its treatment.

  • Program Release: April 1, 2011

  • Program Expiration: April 30, 2012

  • Estimated time to complete: 60 minutes

  • There are no prerequisites for participation.

  • 1 AMA PRA Category 1 Credit™

  • Educational grant provided by Amgen Inc and Dendreon Corporation.

Take CME
mobile news
Visit our mobile news channel today and get the latest Urological reviews, conference coverage, surgical techniques, clinical updates and more!